Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

Core Viewpoint - Inspira Technologies has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its ordinary shares have been trading below $1.00 for 30 consecutive business days [1][2]. Compliance Period and Requirements - The company has been granted a 180-calendar day compliance period until September 8, 2025, to regain compliance by ensuring the closing bid price meets or exceeds$1.00 for at least 10 consecutive business days [2]. - If compliance is not achieved by the deadline, the company may qualify for a second 180-calendar day compliance period, provided it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency [3]. Monitoring and Future Actions - The company plans to monitor the closing bid price of its ordinary shares and will consider options to regain compliance within the specified period [4]. - Despite the notice, the company's ordinary shares will continue to be listed and traded on the Nasdaq Capital Market during this compliance period [4]. Company Overview - Inspira Technologies is focused on developing innovative respiratory support and diagnostic technologies, with its flagship product, the INSPIRA ART system, designed to improve critical care by stabilizing oxygen levels without mechanical ventilation [6]. - The INSPIRA ART100 system has received regulatory approvals for use in cardiopulmonary bypass procedures in both the U.S. and Israel [6]. - The company is also developing the HYLA™ blood sensor technology for continuous, real-time blood monitoring without blood draws, along with other pipeline products that are currently in development [6].